These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 35276407)

  • 1. Utilization of macrolides. State of the art 2022 Spilf and GPIP.
    Stahl JP; Castan B; Bonnet E; Bru JP; Cohen R; Diamantis S; Faye A; Hitoto H; Issa N; Lesprit P; Maulin L; Poitrenaud D; Raymond J; Strady C; Varon E; Verdon R; Vuotto F; Welker Y; Gauzit R
    Infect Dis Now; 2022 Aug; 52(5):252-266. PubMed ID: 35276407
    [No Abstract]   [Full Text] [Related]  

  • 2. Anti-infectious treatment duration: The SPILF and GPIP French guidelines and recommendations.
    Gauzit R; Castan B; Bonnet E; Bru JP; Cohen R; Diamantis S; Faye A; Hitoto H; Issa N; Lebeaux D; Lesprit P; Maulin L; Poitrenaud D; Raymond J; Strady C; Varon E; Verdon R; Vuotto F; Welker Y; Stahl JP
    Infect Dis Now; 2021 Mar; 51(2):114-139. PubMed ID: 34158156
    [No Abstract]   [Full Text] [Related]  

  • 3. Inaccurate data in meta-analysis of macrolides by Guang-Ying et al.
    Serisier DJ
    Pulm Pharmacol Ther; 2014 Oct; 29(1):89. PubMed ID: 24835168
    [No Abstract]   [Full Text] [Related]  

  • 4. [Do ketolides have real advantages over macrolides?].
    Muñoz Bellido JL; García-Rodríguez JA
    Rev Esp Quimioter; 2003 Sep; 16(3):273-6. PubMed ID: 14702118
    [No Abstract]   [Full Text] [Related]  

  • 5. [Macrolides in modern therapy of bacterial infections. Spectrum of efficacy characteristics and pharmacological activity].
    Budanov SV; Vasil'ev AN; Smirnova LB
    Antibiot Khimioter; 2003; 48(11):15-22. PubMed ID: 15106307
    [No Abstract]   [Full Text] [Related]  

  • 6. Macrolides and mortality in severe community-acquired pneumonia.
    Chalmers JD
    Crit Care Med; 2014 Feb; 42(2):475-7. PubMed ID: 24434459
    [No Abstract]   [Full Text] [Related]  

  • 7. [Bronchiectasis and macrolides].
    Vila-Justribo M; Dorca-Sargatal J; Bello-Dronda S
    Arch Bronconeumol; 2006 Apr; 42(4):206. PubMed ID: 16735021
    [No Abstract]   [Full Text] [Related]  

  • 8. [Clinical applications of macrolides for respiratory diseases in China].
    Qu JM; Zhang J
    Zhonghua Jie He He Hu Xi Za Zhi; 2008 Oct; 31(10):725-6. PubMed ID: 19080594
    [No Abstract]   [Full Text] [Related]  

  • 9. [New therapeutic uses of the macrolides].
    Mihălţan F
    Pneumologia; 2004; 53(3):100-4. PubMed ID: 16108157
    [No Abstract]   [Full Text] [Related]  

  • 10. Recent Understanding of Role of Macrolides in Rhinosinusitis.
    Kim CH
    Jpn J Antibiot; 2013 Jul; 67 Suppl A():53. PubMed ID: 26688956
    [No Abstract]   [Full Text] [Related]  

  • 11. Macrolides for treatment of chronic obstructive pulmonary disease.
    Sun XJ; He ZY
    Chin Med J (Engl); 2019 Jun; 132(11):1261-1263. PubMed ID: 30973449
    [No Abstract]   [Full Text] [Related]  

  • 12. Questions remain regarding mandatory use of macrolides in community-acquired pneumonia.
    Westley BP; Chan PA
    Intensive Care Med; 2010 Oct; 36(10):1787. PubMed ID: 20631988
    [No Abstract]   [Full Text] [Related]  

  • 13. [Clinical basis of macrolides apply in diseases of the respiratory tract].
    Płusa T
    Pol Merkur Lekarski; 2008 Nov; 25(149):432-6. PubMed ID: 19177783
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Immunomodulating effects of macrolides: areas of possible clinical use in pulmonology].
    Sinopal'nikov AI
    Ter Arkh; 2011; 83(8):10-20. PubMed ID: 21961326
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Macrolides in chronic inflammatory skin disorders.
    Alzolibani AA; Zedan K
    Mediators Inflamm; 2012; 2012():159354. PubMed ID: 22685371
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Macrolides in community-acquired pneumonia: does the bell toll for thee?
    Granowitz EV; Brown RB
    Chest; 2005 Sep; 128(3):1089-93. PubMed ID: 16162689
    [No Abstract]   [Full Text] [Related]  

  • 17. [New macrolides or a promise for noninvasive treatment in patients with acute bacterial sinusitis].
    Ovchinnikov AIu; Shevtsov EA; Paniakina MA
    Vestn Otorinolaringol; 2010; (5):64-7. PubMed ID: 21191360
    [No Abstract]   [Full Text] [Related]  

  • 18. Preventing COPD exacerbations with macrolides: a review and budget impact analysis--author response to letter to the editor.
    Simoens S; Laekeman G; Decramer M
    Respir Med; 2014 Jul; 108(7):1065. PubMed ID: 24849292
    [No Abstract]   [Full Text] [Related]  

  • 19. Immunomodulatory properties of macrolides: overview and historical perspective.
    Rubin BK
    Am J Med; 2004 Nov; 117 Suppl 9A():2S-4S. PubMed ID: 15586557
    [No Abstract]   [Full Text] [Related]  

  • 20. Comments on Zhuo et al.: prolonged treatment with macrolides in adult patients with non-cystic fibrosis bronchiectasis: meta-analysis of randomized controlled trials.
    Li M; Jiang D; Yu S; Wang Y; Wang Y
    Pulm Pharmacol Ther; 2015 Feb; 30():93-5. PubMed ID: 25549569
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.